Phase 3 trial shows Dupixent improves EoE in children, while benralizumab offers no relief.
Two studies published in The New England Journal of Medicine reveal mixed progress in treating eosinophilic esophagitis (EoE). A positive Phase 3 trial shows that Dupixent, an FDA-approved drug for EoE, improved key disease measures in children aged 1 to 11, achieving histologic remission. However, a separate study found that benralizumab, previously approved for adults and teens, provided no relief to EoE patients.
June 26, 2024
7 Articles